These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24912253)

  • 21. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ; Singh H; Diaz J; Peters JI
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventive therapy of asthma steroid and other antiasthmatic drugs.
    Nagy L
    Acta Microbiol Immunol Hung; 1998; 45(1):131-4. PubMed ID: 9595163
    [No Abstract]   [Full Text] [Related]  

  • 24. An update on biologic-based therapy in asthma.
    Walsh GM
    Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
    Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
    J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids.
    Domingo C; Moreno A; Mirapeix R
    Intern Med J; 2011 Jul; 41(7):525-36. PubMed ID: 21762333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of methacholine challenges in a multicenter pediatric asthma study.
    Covar RA; Colvin R; Shapiro G; Strunk R
    J Allergy Clin Immunol; 2006 Mar; 117(3):709-11. PubMed ID: 16522478
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
    Aksu K; Kurt E
    Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
    [No Abstract]   [Full Text] [Related]  

  • 30. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Airway remodeling: therapeutic target or not?
    Szefler SJ
    Am J Respir Crit Care Med; 2005 Apr; 171(7):672-3. PubMed ID: 15790863
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
    Moss RB
    Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
    Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
    QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chinese herbal anti-asthma tea to go!
    Wang YH; Hogan SP
    Clin Exp Allergy; 2010 Nov; 40(11):1590-2. PubMed ID: 21039969
    [No Abstract]   [Full Text] [Related]  

  • 36. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?
    Inman M
    Eur Respir J; 2004 Jul; 24(1):1-2. PubMed ID: 15293595
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety of omalizumab in asthma.
    Tan RA; Corren J
    Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strict adherence rules to obtain monoclonal therapy might cost lives.
    Green RH; Shaw D
    Lancet Respir Med; 2017 Sep; 5(9):678-679. PubMed ID: 28666608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.